Rare disease

Clinical research
#Drug discovery #LifeArc #Rare disease #Research and development

LifeArc’s £40m research centres to boost research into rare diseases

Four new LifeArc Translational Centres for Rare Diseases have been created to give people living with rare medical conditions access to improved tests and treatments. The virtual centres will focus on areas where there are significant unmet needs. They aim to tackle barriers that ordinarily prevent… Read More

#News

A strip of 8 PCR tubes on the thermal cycler
#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #Gene mutation #Phase I trial #Rare disease

Potential first-in-class therapeutic for urea cycle disorders enters trial

CAMP4 Therapeutics has dosed the first participant in its Phase I clinical study of CMP-CPS-001, a potential first-in-class therapeutic for the treatment of urea cycle disorders (UCDs). UCDs are a group of rare, severe, inherited metabolic diseases impacting protein metabolism. Mutations in genes encoding urea cycle… Read More

#News

Kidneys
#Chronic kidney disease (CKD) #Kidney disease #Rare disease #UK Kidney Association #University College London

Focus on rare disease treatments to beat kidney failure, says study

Focusing on rare conditions could significantly reduce the burden of kidney disease, according to a new study led by University College London (UCL) and the UK Kidney Association. The study, published in The Lancet to mark World Kidney Day on 14 March, draws on the largest… Read More

#News

Gene therapy
#Cell and gene therapy #FDA #Gene therapy #Orchard Therapeutics #Paediatrics #Rare disease

First gene therapy for children with rare disease gets US sign-off

Lenmeldy (atidarsagene autotemcel) has become the first Food and Drug Administration (FDA)-approved gene therapy for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD). Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system. It is… Read More

#News #Regulatory #Trending News

Demyelination of neuron
#Antisense Oligonucleotides (ASOs) #FDA #Orphan drugs #Rare disease #SynaptixBio

FDA Orphan Drug Designation awarded to rare disease therapies

UK-based biotech SynaptixBio has secured a second Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA). The company received its first ODD in early 2023 for a therapeutic that targets Hypomyelination with Atrophy of the Basal ganglia and Cerebellum (H-ABC), the most severe form of TUBB4A leukodystrophy. Read More

#News #Regulatory

Rare Disease Day
#Orphan drugs #Rare cancers #Rare disease #Rare Disease Day

Five 2024 breakthroughs in the treatment of rare diseases

For Rare Disease Day 2024, Diana Spencer provides a round-up of the latest breakthroughs in the treatment of rare disease. Study reveals therapeutic potential of mRNA in rare diseases Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare… Read More

#News

#Clinigen #Early access #Education #Rare disease #Unlicensed drug

A third of rare disease patients unaware of early access programmes

One-third (32%) of rare disease patients are not aware they can access unlicensed medicines through Early Access Programmes, new research has revealed. However, two-thirds (68%) of patients are comfortable receiving medicines before they’re licensed through their country’s healthcare system. The new data was released… Read More

#News

Stamp of approval
#Blood cancer #GSK #MHRA #Oncology #Rare disease

JAK inhibitor for rare blood cancer approved in Great Britain

GSK’s Omjjara (momelotinib) has been granted marketing authorisation in Great Britain for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. It is approved in patients who are Janus kinase (JAK)… Read More

#News #Regulatory

Blood cancer
#Acute Myeloid Leukaemia #FDA #Oncology #Orphan drugs #Pleco Therapeutics #Rare disease

Novel leukaemia drug receives FDA Orphan Drug Designation

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics’s lead compound PTX-252 for the treatment of acute myeloid leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. The FDA’s designation acknowledges the potential of PTX-252… Read More

#Cancer Research #News #Regulatory

Pancreatic cancer
#AI #ASCO #Cancer research #Clinical trials #FDA #Neurology #Oncology #Orphan drugs #Pancreatic cancer #Rare disease

Phase IIa results for combination pancreatic cancer therapy  

BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, has announced new data from a Phase IIa clinical trial of its lead candidate, BPM31510, in patients with advanced pancreatic cancers at the annual ASCO Gastrointestinal Cancers Symposium, being held 18-20 January 2024, in San Francisco. Read More

#Cancer Research #News

mRNA
#King's College London #Liver disease #Moderna #Mouse models #mRNA #Rare disease #University College London

Study reveals therapeutic potential of mRNA in rare diseases

Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people. The team, led by University College London (UCL), King’s College London and Moderna scientists, found that mRNA could be… Read More

#Editor's Choice #News

Cell engineering
#Cell therapy #Engineered cells #Immusoft #Phase I trial #Rare disease

World’s first engineered B cell therapy enters human trials

The first patient has been dosed with an engineered B cell investigational therapy in a Phase I trial in Mucopolysaccharidosis type I (MPS I). Developer Immusoft has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for the therapy, designated ISP-001, in this indication. Read More

#Editor's Choice #News

Cancer research
#Clinical trials #Paediatrics #Pharming #Phase III trial #Rare disease

Trials investigate targeted APDS treatment in a paediatric setting

The first patient has been dosed in a Phase III study evaluating a paediatric granulated formulation of leniolisib in children with activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming’s investigational drug leniolisib is an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. At sites in the… Read More

#News

Enzymes
#Chiesi #Enzymes #Genetic diseases #National Institute for Health and Care Excellence (NICE) #Rare disease

NICE okays enzyme replacement therapy for alpha-mannosidosis

Chiesi’s Lamzede (velmanase alfa) will now be funded on the NHS in England and Wales as an option for treating the non-neurological signs and symptoms of mild to moderate alpha-mannosidosis following a recommendation by the National Institute for Health and Care Excellence (NICE). The treatment must be started in people… Read More

#News #Regulatory

Blood cells
#FDA #Gene mutation #Genetic diseases #Rare disease #Takeda

First therapy for very rare blood clotting disorder gets US greenlight

Takeda’s Adzynma has become the first recombinant protein product approved in the US for prophylactic or on-demand enzyme replacement therapy (ERT) for congenital thrombotic thrombocytopenic purpura (cTTP). A very rare, inherited blood clotting disorder, cTTP is caused by a disease-causing mutation in the ADAMTS13 gene, which is responsible for making… Read More

#Editor's Choice #News #Regulatory

The microbiome
#Alzheimer's #Antibodies #Cancer #Covid-19 #Rare disease #Therapeutic Antibodies

Which diseases will benefit from therapeutic antibody development?

Listen to this article on the DDW Podcast: DDW’s Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies. Cancer Monoclonal antibodies (mAbs) are a type of targeted drug therapy, and as such are often used to treat cancer. Alongside surgery, radiation and chemotherapy, antibody-based immunotherapy… Read More

#Exclusive Content